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3Abstract41
The infant gut microbiota undergoes dramatic changes during the first two years42
of life. The acquisition and development of this population can be influenced by43
numerous factors, with antibiotic treatment being suggested as being among the44
most significant. Despite this, however, there have been relatively few studies45
which have investigated the short-term recovery of the infant gut microbiota46
following antibiotic treatment. The aim of this study was to use high-throughput47
sequencing (employing both 16S rRNA and rpoB specific primers) and48
quantitative PCR to compare the gut microbiota of 9 infants who underwent49
parenteral antibiotic treatment with ampicillin and gentamycin (within 48 hours of50
birth), 4 and 8 weeks after the conclusion of treatment, relative to that of 951
matched healthy controls. The investigation revealed that the gut microbiota of52
the antibiotic-treated infants had significantly higher proportions of Proteobacteria53
(p=0.0049) and significantly lower Actinobacteria (p=0.00001), (and the54
associated genus Bifidobacterium (p=0.0132)) as well as the genus Lactobacillus55
(p=0.0182) compared with the untreated controls 4 weeks after the cessation of56
treatment. By week 8, the Proteobacteria remained significantly higher in the57
treated infants (p=0.0049) but the Actinobacteria, Bifidobacterium and58
Lactobacillus levels had recovered and were similar to the control samples.59
Despite this recovery in total Bifidobacterium numbers, rpoB-targeted60
pyrosequencing revealed that the number of different Bifidobacterium species61
present in the antibiotic-treated infants was reduced. It is thus apparent that the62
combined use of ampicillin and gentamycin in early life can have significant63
4effects on the evolution of the infant gut microbiota, the long-term health64
implications of which remain unknown.65
5Introduction66
It is becoming increasingly evident that the composition of the human gut67
microbiota can have a significant impact on health and disease (47, 64, 69, 74).68
Indeed, several studies have highlighted the role gut microbes play in diverse69
and important functions in the body including, for example, vitamin synthesis,70
immune system development and toxin metabolism (27, 30). Furthermore, there71
have been a number of studies which have suggested associations between an72
altered gut microbial composition and Crohn’s disease (28), irritable bowel73
syndrome (42), obesity (46, 51) and other diseases/syndromes. These studies74
have highlighted the importance of developing and maintaining a ‘healthy’ gut75
microbiota. Indeed, it has recently been established that the fact that the immune76
system of germ free mice is not exposed to commensal microbes in early life can77
lead to increased numbers of invariant natural killer T cells, which in turn caused78
inflammation on exposure to particular microbes, resulting in an increased risk of79
both colitis and asthma (54). The infant gut microbiota is established early in life80
such that, although the infant gut is sterile in utero, by the time the infant reaches81
the age of two years, this microbiota resembles that of an adult (3).82
Consequently, this period of the infant’s life represents a unique window of83
opportunity during which time the gut microbiota may be modified with84
implications for health outcomes (56). A myriad of factors that affect this85
composition have been investigated and include mode of delivery (56), feeding86
choice (i.e. breast versus formula feeding) (8, 45), prematurity (63, 72), and the87
administration of probiotics (11, 15, 55, 60) and prebiotics (10, 31, 65). It is also88
6thought that exposure to antibiotics can have a significant negative influence on89
the composition and development of the gut microbiota in early life (7, 23, 35).90
Antibiotics by their very nature are designed to target and inhibit microorganisms91
in a variety of ways. The majority of those used clinically have a broad spectrum92
of activity and, as a consequence, in addition to controlling pathogenic bacteria,93
have the potential to inflict collateral damage on commensal gut bacteria (9),94
including genera that can often have health-promoting roles, such as the95
bifidobacteria and lactobacilli. Thus far, the most in-depth investigations into the96
nature and extent of this collateral damage have relied on the use of denaturing97
gradient gel electrophoresis (DGGE) (23) and have revealed that antibiotic98
exposure in infancy results in significant decreases in bifidobacteria, lactobacilli99
and Bacteroides levels compared to control infants.100
More recently, the impact of antibiotic administration on the gut microbiota has101
been revealed in even greater depth as a consequence of the use of high-102
throughput sequencing technologies in both animal and human trials (6, 17, 18,103
51, 58, 66). These studies have shown that antibiotics can dramatically alter the104
gut microbiota, with the effects depending on factors such as the specific105
antibiotic administered, the spectrum of inhibition and the duration of treatment106
(67). While antibiotic administration in adults can have a number of gut107
microbiota-mediated consequences, such as an increased susceptibility to108
Clostridium difficile associated diarrhoea (14) there is also evidence to suggest109
that perturbation of the infant gut microbiota during its rapid developmental phase110
can have even more significant consequences. Indeed, for example, an111
association between antibiotic administration in early life and an increased risk of112
7asthma and allergies, such as atopic eczema, in later life has been noted113
previously (1, 44, 59). Thus, developing a detailed understanding of the impact of114
specific antibiotics on the infant gut microbiota is vital in order to begin to115
understand the mechanism(s) by which these changes could increase the risk of116
disease. It is thus notable, that the impact of antibiotics on the composition of the117
infant gut microbiota has yet to be assessed through high-throughput sequencing118
technologies. Here we address this issue, by using 454-pyrosequencing119
technology together with quantitative PCR (qPCR), to reveal the short-term (4-8120
weeks) consequences of the treatment of infants with a combination of ampicillin121
and gentamycin within the first 48 hours of birth.122
8Materials and Methods123
Participants124
Approval for this trial was received from the Clinical Research Ethics Committee125
of the Cork Teaching Hospitals, Cork, Ireland. Details on inclusion criteria,126
sample collection and storage have been outlined previously (35). Briefly, 18127
infants were recruited, 9 of whom had received parenteral antibiotic treatment128
with a combination of ampicillin and gentamycin within 48 hours of birth, and 9129
untreated controls. Exclusion criteria included premature birth, requiring oral130
antibiotics, being on nil by mouth, infants who required surgery or those with131
congenital abnormalities. Faecal samples were collected 4 and 8 weeks after the132
cessation of antibiotic treatment. Of the 18 infants, 8 had been breastfed and 10133
formula fed, while 13 were born vaginally and 5 by Caesarean section (Table 1).134
135
Generation of 16S rRNA amplicons for high-throughput sequencing136
The generation of 16S rRNA amplicons was performed as described previously137
(51). Total bacterial DNA was extracted from the faecal samples using the138
QIAamp DNA Stool Mini Kit (Qiagen, West Sussex, UK) (35). DNA was frozen at139
-80°C prior to PCR amplification. 16S rRNA bacterial gene amplicons (V4) were140
generated with a view to high-throughput sequencing using the Roche Genome141
Sequencer FLX platform. These amplicons, 239 nucleotides in length, were142
generated using one forward, i.e. F1 (5’ AYTGGGYDTAAAGNG), and a143
combination of 4 reverse primers, R1 (5’ TACCRGGGTHTCTAATCC), R2 (5’144
TACCAGAGTATCTAATTC), R3 (5’ CTACDSRGGTMTCTAATC) and R4 (5’145
9TACNVGGGTATCTAATC). These primers also contained an A (F primer) or B146
(R primers) adapter and different versions of the F primer (each containing a147
distinct multiple identifier (MID)) were employed for each sample. PCRs were148
completed on a G-storm PCR machine under the following conditions: heated lid149
110°C, 94°C for 2 min followed by 35 cycles of 94°C for 1 min, 52°C for 1 min150
and 72°C for 1 min followed by a temperature step of 72°C for 2 min and held at151
4°C. PCRs had a final volume of 50µl made up of 25 µl of Biomix Red (MyBio,152
Ireland), 1 µl forward primer (0.15µM), 1 µl reverse primer (0.15µM) (mix of 4),153
template DNA and sterile PCR grade water. All samples were completed in154
duplicate. PCR products were analysed by agarose gel electrophoresis (1.5% in155
1x TAE buffer). Following this, PCR products were cleaned using Agentcourt156
AMPure kit (Beckman Coulter Genomics, UK) as per manufacturer’s protocol.157
Samples were then quantified using the Quant-iT Picogreen quantification kit158
(Biosciences, Ireland) and the Nanodrop 3300 (Thermo Scientific, Ireland).159
Equimolar solutions of samples were then pooled for sequencing. These pooled160
samples were then cleaned and re-quantified (as before). Emulsion based clonal161
amplification was completed as part of the 454-pyrosequencing process.162
Sequencing took place at the Teagasc 454 Sequencing facility on a Genome163
Sequencer FLX platform (Roche Diagnostics Ltd, West Sussex, UK) according to164
the manufacturer’s protocols.165
166
Generation of Bifidobacterium-derived rpoB amplicons for high-throughput167
sequencing168
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A set of PCR primers, which have been used previously to facilitate the169
identification of bifidobacteria (43), and which amplify a 351 bp region from the170
Bifidobacterium RNA polymerase β-subunit gene, rpoB, were also utilized in this171
study. Twelve week 4 and twelve week 8 samples were selected and amplified172
using these primers which had MID tags and 454 adapters attached, allowing173
pooling of the samples for sequencing while also enabling downstream174
separation of individual results for analysis (Table S1). PCRs were completed on175
a G-storm PCR machine under the following conditions: heated lid 110°C, 94°C176
for 2 min followed by 35 cycles of 94°C for 1 min, 60°C for 1 min and 72°C for 1177
min followed by a temperature step of 72°C for 2 min and held at 4°C. PCRs had178
a final volume of 50µl containing 25 µl of Biomix Red (MyBio, Ireland), 1 µl179
forward primer (0.15µM) (BC1 5’-TCGATCGGGCACATACGG), 1 µl reverse primer180
(0.15µM) (Rev 1 5’-CGACCACTTCGGCAACCG), template DNA and sterile PCR181
grade water. All samples were completed in duplicate. All other steps for182
sequencing (cleaning, quantifying, pooling etc.) were completed as outlined183
above.184
185
Bioinformatic analysis186
Raw 16S rRNA sequencing reads were quality-trimmed using a locally installed187
version of the Ribosomal Database Project (RDP) Pyrosequencing Pipeline188
applying the criteria as previously described (53). Trimmed FASTA sequences189
were then BLASTed (5) against a previously published 16S-specific database190
(70) using default parameters. The BLAST output was then parsed using191
MEGAN software (version 4.6)(34), which assigns reads to NCBI taxonomies by192
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employing the Lowest Common Ancestor algorithm. Bit scores from within193
MEGAN were used to filter the results prior to tree construction and194
summarization. A bit-score of 86 was selected, as previously used for 16S195
ribosomal sequence data (70). Phylum, family and genus counts for each subject196
were extracted from MEGAN. Clustering and diversity analysis of the sequence197
data was performed using the MOTHUR software package (61, 62). For198
Bifidobacterium analysis, raw rpoB sequencing reads were quality trimmed as199
above, with read-lengths for the rpoB amplicon above 300 bp being used.200
Trimmed FASTA sequences were then BLASTed (5) against the NCBI non-201
redundant database using default parameters. The resulting BLAST output was202
parsed through MEGAN using default parameters (34).203
204
qPCR-based determination of total bacteria and total bifidobacteria205
numbers206
Absolute quantification of total bacterial numbers (from 8 representative infants,207
infants B, F, G, H, K-N) and total bifidobacteria numbers (from 9 representative208
infants, infants B, F, G, H, K-O) was carried out by qPCR using the Roche 480209
Lightcycler platform. To determine total bifidobacteria counts, the primers g-Bifid-210
F (5’-CTCCTGGAAACGGGTGG) and g-Bifid-R (5’-211
GGTGTTCTTCCCGATATCTACA) were used (49). Bifidobacterium longum212
ATCC 8809 was used as a reference strain to generate a standard curve for total213
bifidobacteria quantification (21). B. longum was grown overnight anaerobically at214
37°C in modified MRS broth (Difco) (0.05% cysteine) (Sigma Aldrich). Total215
bacterial DNA was then isolated using High Pure PCR template preparation kit216
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(Roche Diagnostics, West Sussex, United Kingdom) as per manufacturer’s217
instructions, and used to establish a standard curve on the Lightcycler 480218
platform (Roche Diagnostics, West Sussex, United Kingdom). Total bifidobacteria219
numbers were quantified using the following programme: 95°C for 5 min followed220
by 50 cycles of 95°C for 10s, 60°C for 20s and 72°C for 20s followed by melting221
curve analysis of 95°C for 5s, 65°C for 1 min and 97°C continuously, followed by222
cooling at 40°C for 10s. Reactions took place in a 20 µl volume made up of 3 µl223
PCR grade water, 1 µl g-Bifid-F (0.15 µM), 1 µl g-Bifid-R (0.15 µM), 5 µl DNA224
template and 10 µl SYBR green (Roche Diagnostics, West Sussex, United225
Kingdom). To quantify total 16S rRNA bacterial counts, a standard curve was226
established using copy numbers of 16S rRNA/µl from 109-102 copies 16S227
rRNA/µl. Values were then converted to copies 16S rRNA/g wet stool using a228
previously outlined calculation (73). The following programme was used to229
quantify total bacterial numbers: 95˚C for 5 minutes followed by 35 cycles of 95˚C230
for 20s, 51˚C for 20s and 72˚C for 20s followed by melting curve analysis of 95˚C231
for 5s, 46˚C for 1 min and 97˚C continuously and a final cooling at 40˚C for 10s.232
Samples contained 2 µl of PCR grade water, 1 µl of forward primer F1 (5’-233
AYTGGGYDTAAAGNG) (0.15 µM), 1 µl of the reverse primer R1 (5’-234
TACCRGGGTHTCTAATCC) (0.15 µM), 1 µl template DNA and 5 µl of SYBR235
green (Roche Diagnostics, West Sussex United Kingdom), giving a final reaction236
volume of 10 µl. Samples were run in quadruplicate, while negative controls237
(where template DNA was replaced with PCR grade water) and standards were238
run in triplicate.239
240
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Statistical Analysis241
Minitab Release 15.1.1.0 (Minitab Inc. 2007) was used to perform non-parametric242
statistical analysis (Mann Whitney test) when comparing 2 specific subject243
groups to determine the impact of antibiotic treatment on the microbiota.244
Statistical significance was accepted at p<0.05.245
246
Results247
High-throughput sequencing of 16S rRNA amplicons from the faecal248
samples of antibiotic-treated and control infants249
Eighteen infants, 9 of whom had been treated with a combination of parenteral250
ampicillin and gentamycin within 48 hours of birth, and 9 controls who had251
received no antibiotic treatment, were recruited (35). Faecal samples were252
collected 4 and 8 weeks after the cessation of antibiotic treatment and faecal253
DNA was extracted and used as a template to generate 16S rRNA amplicons,254
with a view to determining the composition of the gut microbiota through next255
generation sequencing. Diversity, richness, coverage and evenness estimations256
were calculated for all data sets (Table 2). The Chao 1 calculation is an estimator257
of phylotype richness in a dataset and the Shannon index of diversity reflects258
both the richness and the community evenness (i.e. proportional phylotype259
abundance). The diversity index was above 3.6 in all samples, indicating an260
overall high level of biodiversity (Table 2). The Good’s coverage, a measure of261
sampling completeness, at the 97% similarity level ranged between 88.6-96.1%262
for the datasets. The lowest value was obtained for the control samples at week263
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8 and is a reflection of the more diverse nature of the microbiota present (Table264
2).265
266
Composition of the gut microbiota of antibiotic-treated and control infants267
4 weeks after the conclusion of treatment268
Bioinformatic analysis of 16S rRNA sequence data revealed that there were269
significant differences in the gut microbiota of antibiotic-treated infants compared270
with untreated controls 4 weeks following the cessation of antibiotic treatment.271
Statistically higher proportions of reads corresponding to the phylum272
Proteobacteria were detected in the antibiotic-treated samples compared with the273
control samples (p=0.0049) (Fig. 1). Indeed, the gut microbiota of the antibiotic-274
treated infants was dominated by Proteobacteria, accounting for 54% of all275
bacteria present, compared to just 37% in the untreated controls (Fig. 1). While276
Proteobacteria, Firmicutes and Actinobacteria were found in all antibiotic-treated277
infants at week 4, Bacteroidetes were detected in less than half of these infants278
and, in those where they were detected, levels were notably low (Fig. 1 & SI Fig.279
1). Actinobacteria were also significantly lower in the antibiotic-treated samples280
than in the controls (3% vs. 24%; p=0.00001).281
At the family level, the antibiotic-treated samples had significantly higher282
numbers of Enterobacteriaceae (55% vs. 37%; p=0.0073) and283
Peptostreptococcaceae (23% vs. 2%; p=0.0381) compared to the control infants284
at week 4 (Fig. 2). Significantly lower numbers of Bifidobacteriaceae (3% vs.285
24%; p=0.0132) were also evident in the antibiotic-treated samples at week 4. In286
addition antibiotic treatment also resulted in significant differences at genus level287
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relative to the controls at this time (Fig. 3). Significantly higher levels of288
Bifidobacterium (25% vs. 5%; p=0.0132) and Lactobacillus (4% vs. 1% p=0.0088)289
were present in the untreated controls compared to the antibiotic-treated infants.290
Additionally, the gut microbiota of the antibiotic-treated infants displayed limited291
diversity, as they were dominated by genera within the Enterobacteriaceae292
family, with levels of these bacteria being statistically significantly higher in the293
antibiotic-treated infants compared to the controls (p=0.0073). This pattern was294
also apparent with respect to proportions of the Firmicutes-associated genus295
Clostridium (p=0.0033). Additionally, there was a significantly higher level of296
enterococci in the treated infants compared to the controls at week 4 (p=0.0172).297
Despite the fact that the diversity of antibiotic-treated and control samples did not298
differ significantly (p=0.5752) (Table 2), the overall numbers of genera detected299
in the antibiotic-treated samples was notably lower than in the controls, reflecting300
the restriction in diversity and the dominance of the members of the301
Proteobacteria and the persistent effects of antibiotic treatment 4 weeks after302
administration ceased.303
304
Composition of the gut microbiota of antibiotic-treated and control infants305
8 weeks after the conclusion of treatment306
Bioinformatic analysis of the 16S rRNA sequence data revealed that, the week 8307
samples from the antibiotic-treated infants contained significantly higher308
proportions of Proteobacteria (44%) compared to controls (23%) (p=0.0049).309
Eight weeks after the cessation of antibiotic treatment Proteobacteria continued310
to be the dominant phylum present in antibiotic-treated infant samples despite the311
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fact that the proportions of Proteobacteria reads decreased significantly between312
week 4 and week 8 (p=0.0136). During the same period the proportion of313
Actinobacteria reads increased significantly (p=0.0055) in the antibiotic-treated314
infant samples, to the extent that they no longer differed significantly from those315
in the control samples (p=0.1164). Nonetheless, a more diverse gut microbe316
population was observed in the controls relative to the antibiotic-treated samples317
8 weeks after antibiotic treatment (Shannon’s index for diversity was 3.8 and 4.6318
in the treated and control infants, respectively) (Fig. 1 & Table 2). Analysis of319
data from individual infants also revealed that the recovery of the infant gut320
microbiota to one more comparable to that of the controls was also dependent on321
the duration of treatment (data not shown). For example, the gut microbiota of the322
infant who underwent the longest antibiotic treatment period (infant A, treated for323
9 days) displayed the most limited recovery of all treated infants. This infant’s gut324
microbiota was populated predominantly by Proteobacteria, and this phylum325
remained dominant at week 8, at which time it accounted for 67% of all of the326
bacteria detected (Fig. S1).327
At the family level at week 8, the Enterobacteriaceae remained dominant in the328
antibiotic-treated infants (45%), despite having significantly decreased in329
proportion relative to week 4 (p=0.0136) (Fig. 2). During the same interval,330
proportions of Enterobacteriaceae decreased in the control infants (37% at week331
4 vs. 24% at week 8). In the antibiotic-treated group, there was also a significant332
decrease in levels of Peptostreptococcaceae between week 4 and week 8333
(p=0.0014) whereas a significant increase (p=0.0182) in the Bifidobacteriaceae334
levels occurred during this 4 week interval, to the extent that the proportions of335
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this family in the antibiotic-treated and control samples no longer differed336
significantly by week 8 (p=0.3927).337
At genus level, the gut microbiota of the antibiotic-treated infants remained338
predominantly populated with members of the Enterobacteriaceae family, which339
accounted for half of all of the genera detected at week 8. The numbers of these340
bacteria were significantly higher in the antibiotic-treated infants than in the341
control samples at week 8 (p=0.0061). In contrast, Bifidobacterium numbers were342
similar in the controls and antibiotic-treated samples at this time (19% vs. 15%,343
p=0.3927). This was as a consequence of the fact that the proportions of344
Bifidobacterium had increased significantly in the antibiotic-treated samples345
during this 4 week interval (p=0.0182). Significant differences in the levels of346
Lactobacillus no longer existed at week 8 between the 2 groups (p=0.3253) (Fig.347
3), due to a trend towards a significant recovery in Lactobacillus proportions in348
the antibiotic-treated samples (p=0.059) during this interval. In addition,349
Clostridium proportions remained higher in the treated infants compared to the350
controls at week 8 (7% vs. 2%; p=0.0345), as a consequence of the fact that351
there was no significant change in the levels of Clostridium in the antibiotic-352
treated infants between weeks 4 and 8 (p=0.6132). By week 8 there was no353
longer a significant difference in the proportions of enterococci seen in the354
treated infants compared to the controls (p=0.1105).355
356
qPCR-based determination of total bacteria and total bifidobacteria357
numbers358
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To determine the impact of antibiotic treatment on the total number of bacteria359
and of bifidobacteria, absolute quantification was completed using qPCR, with a360
representative subset of samples. The qPCR results revealed that all infants, i.e.361
both treated and controls, had 107-108 copies of the 16S rRNA gene/g wet stool362
(Table 3) and established that no significant differences existed between total363
16S rRNA gene copies (which is representative of total bacteria numbers) when364
values for antibiotic-treated infant samples were compared to those for controls365
at week 4 (p=0.7667) or week 8 (p=0.7918). However, a statistically significant366
increase in total 16S rRNA values did occur in the antibiotic associated samples367
(p=0.0005) between weeks 4 and 8. With respect to total bifidobacteria numbers,368
it was established that counts in both the treated and control samples ranged369
from 106-107 CFU/g wet stool (Table 4). There was no significant difference in the370
average bifidobacteria numbers of the antibiotic-treated infants relative to the371
controls at week 4 (p=0.4273) or at week 8 (p=0.1548). Furthermore, in the372
majority of individual infants, the total bifidobacteria numbers did not differ373
significantly between the two time points (Table 4).374
375
Specific assessment of the composition of the gut Bifidobacterium376
population in antibiotic-treated and control infants377
Given the health benefits that have been attributed to many strains of378
Bifidobacterium, a strategy was implemented to specifically assess the impact of379
antibiotic treatment on gut bifidobacteria. This again relied on the use of high-380
throughput sequencing but in this instance focused on the sequencing of381
amplicons corresponding to a region of the Bifidobacterium sp. RNA polymerase382
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β-subunit gene, rpoB, using a set of primers which have been used previously for383
bifidobacterial species identification (43) but, in this instance, contain adapters384
and MIDs to facilitate the sequencing process. These primers demonstrated385
excellent specificity with 99% of the reads at phylum level being assigned to the386
Actinobacteria. The total number of reads for the antibiotic-treated infants at387
week 4 was 80,034, averaging at 6670 reads per subject and for week 8 was388
36,557, averaging at 3046 reads per subject. While the 16S rRNA data presented389
above showed that antibiotic treatment decreased the proportion of bifidobacteria390
present in the gut microbiota of infants, the rpoB data provides further, more391
detailed insights. More specifically, this analysis revealed that only 2 species392
were detected in the majority of cases in the antibiotic-treated infants, namely B.393
longum and Bifidobacterium breve. In contrast, the controls showed a more394
considerable variation in the composition of individual samples, and even395
between samples from the same individuals at different time points (Fig. 4).396
397
Discussion398
Antibiotics are of fundamental importance to modern medicine and their use has399
been pivotal to the prolongation of human life. Despite this, there are ever400
increasing concerns with respect to the negative consequences of antibiotic401
utilization, including issues revolving around the collateral damage inflicted on the402
commensal microbiota and the implications thereof (9). Short-term health effects403
include antibiotic associated diarrhoea, gastrointestinal discomfort, gastritis and404
glossitis (24) as well as the possible development of antibiotic resistant bacteria405
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populations in the gut (39). Furthermore, it has been suggested that a number of406
long-term health effects are influenced by the development of the gut microbiota407
(38) and, in turn, the immune system in early life (32, 33, 37, 64), with data408
suggesting that antibiotic administration contributes to the risk of developing409
asthma and allergy (13, 25, 40) in addition to heightened risk of obesity (4) later410
in life. The risks associated with disrupting the gut microbiota may be especially411
great in young infants, as antibiotic administration can impact on the commensal412
microbiota at a time when this population is in rapid flux and can easily be413
unbalanced. Despite this concern, there have been no studies to date which have414
used powerful next generation sequencing technologies to assess the microbiota415
of infants who have been administered antibiotics. This study was performed with416
a view to addressing this issue by employing 454-pyrosequencing, together with417
qPCR analysis. The results of this relatively small study are important and418
highlight the apparently major impact that treatment with a combination of419
ampicillin and gentamycin can have on the gut microbiota of infants. It is evident420
that the treated infants suffered significant reductions in potentially beneficial421
bacteria belonging to the phylum Actinobacteria, including Bifidobacterium, as422
well as some members of the Firmicutes phylum, including Lactobacillus. These423
appeared to be replaced by members of the Proteobacteria, including members424
of the Enterobacteriaceae family, thereby resembling trends previously noted in a425
terminal restriction fragment length polymorphism-based study of antibiotic-426
treated infants (68). The dominance of the Proteobacteria, and an overall427
reduced microbial diversity, continued to be evident even 8 weeks after antibiotic428
treatment, despite the fact that populations of potentially beneficial bacteria429
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(including Bifidobacterium) recovered somewhat. Given the fact that sequencing430
data provides results revealing the proportions of different populations present,431
rather than their absolute number, the question as to whether the dominance of432
Proteobacteria is reflective of an outgrowth of this population, or its numbers433
remaining stable among a total bacterial population which is diminished in434
number, exists and some of the more recent sequencing based studies have435
begun to address this issue (51, 58). It is thus important that in this instance436
qPCR data establishes that there is no significant difference between the total437
16S rRNA counts in the treated infants compared to the controls, thereby438
implying Proteobacteria outgrowth, presumably as a consequence of reduced439
competition from other more antibiotic-sensitive gut microbes. Others have also440
documented a corresponding phenomenon of Proteobacteria outgrowth as a441
consequence of antibiotic administration (22, 51, 58). Notably, the frequency of442
beta-lactam antibiotic resistance among Enterobacteriaceae, as a consequence443
of the production of beta-lactamases, has been well established (12, 52, 56, 57).444
The presence of significantly higher levels of enterococci in the antibiotic-treated445
samples 4 weeks after treatment ended is also consistent with the fact that446
ampicillin (41, 71) and gentamycin (20, 36) resistant Enterococcus have been447
identified on numerous occasions. The ability of the administered antibiotics, and448
especially ampicillin, to significantly alter the gut microbiota is also reflective of449
their activity profile. Following parenteral administration, ampicillin is rapidly and450
widely distributed throughout the body resulting in high levels in bile (2) and, once451
excreted, in the gut.452
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It was notable that while the 16S rRNA sequencing data and the total bacteria453
qPCR data correlated well, the assessment of the impact of antibiotic454
administration on relative or total bifidobacteria numbers, as determined by455
sequencing and qPCR respectively, was not consistent. More specifically, qPCR456
analysis at week 4 revealed no significant difference between total bifidobacteria457
values in the antibiotic-treated infants compared to the controls, while the 16S458
sequencing data detected significantly lower proportions in infants that had459
undergone antibiotic treatment. These differences may be accounted for by the460
fact that only a subset of the 18 infants were included in the rpoB-based qPCR461
analysis and, as outlined earlier, individual variations occur in response to462
antibiotic treatment. Furthermore, differences regarding primer specificity463
between those used for qPCR and for total bacterial 16S rRNA sequencing may464
also have contributed to this result.465
The altered gut microbial composition of antibiotic-treated infants is a concern466
given that several members of the Bifidobacterium and Lactobacillus genera467
have been found to possess health-promoting properties, to the extent that they468
are frequently employed as probiotic cultures, whereas many Proteobacteria469
have the potential to become pathogenic given a suitable environment. This470
study also demonstrated that the collateral damage inflicted on the gut microbiota471
through the use of broad spectrum antibiotics is not rapidly repaired, as472
significant differences between the composition of antibiotic-treated and control473
populations were apparent at 4 and 8 weeks post treatment. Previous studies,474
employing temperature gradient gel electrophoresis or DGGE, have also shown475
that antibiotic treatment causes short- to medium-term effects, in some cases476
23
with no bifidobacteria being detected 28 days after treatment ceased (16, 23).477
However, the fact that some recovery was evident in this and previous trials (16,478
35) indicates that the infant microbiota, despite being much less stable than that479
of an adult, is somewhat resilient. Indeed, on average, bifidobacteria populations480
recovered to the extent that both sequencing- and qPCR-based analysis481
revealed that their levels were no longer significantly reduced in the antibiotic-482
treated samples, relative to the controls, at week 8. Critically, however, it was483
apparent that the composition of these Bifidobacterium populations differed from484
one another. This is consistent with previous studies highlighting the differing485
susceptibilities of species of bifidobacteria to antibiotics (22, 23, 48). More486
specifically, in agreement with previous DGGE-based analysis (35), B. longum487
was found to be more dominant in samples from antibiotic-treated infants. This488
may be due to the fact that while all bifidobacteria have previously been found to489
display comparably high levels of sensitivity to gentamycin, strains of B. longum490
have been found to be more ampicillin resistant than other bifidobacteria (50).491
The significant impact of antibiotic administration on the Bifidobacterium492
population at the species level suggests that many other species are similarly493
impacted upon by antibiotic administration, something which warrants further494
investigation.495
It is important to note that factors other than antibiotic administration may also496
contribute to the differences in the gut microbial composition of the cohort of497
infants that were the focus of this investigation. From this perspective, it is498
notable that the majority of antibiotic-treated infants were delivered by Caesarean499
section, while the controls were all delivered vaginally. This is particularly500
24
relevant as numerous studies have noted the presence of an altered gut501
microbiota profile in Caesarean delivered infants (3, 19, 26). Caesarean delivered502
infants have significantly altered profiles compared to vaginally delivered infants,503
due to a lack of colonization with their mother’s vaginal microbiota during delivery504
and are instead colonized by skin microbiota (predominantly Staphylococcus and505
Corynebacterium (19)). However, it has also been previously demonstrated that506
while levels of Bifidobacterium were significantly lower in Caesarean delivered507
infants compared to vaginally delivered infants, Bifidobacterium levels were508
comparable by 1 month of age (29). This was not the case in our study, in that all509
antibiotic-treated infants (regardless of delivery mode) had significantly lower510
levels of Bifidobacterium at 1 month of age and, even at 2 months of age511
possessed, a gut microbiota which was altered relative to the control group. It is512
also worth noting that although our microbiota-related data is presented as an513
average, we also possessed the microbiota-related data (both high throughput514
sequencing and qPCR derived) from each infant. Analysis of this data failed to515
reveal significant differences between the microbial populations of the vaginally516
delivered and Caesarean delivered infants subgroups of the antibiotic treated517
infants (data not shown). Thus, while we acknowledge that delivery mode may518
influence the microbial composition of the infants studied, it would seem not to be519
as significant a factor as antibiotic administration.520
Another factor that merits consideration relates to breastfeeding. While there are521
a considerable numbers of publications regarding the benefits of breastfeeding522
with respect to the development of the infant gut microbiota (8, 56), in this study523
breastfeeding did not provide any additional protection to the infant gut524
25
microbiota against the impact of antibiotic treatment. A failure to observe525
protection could well be due to the relatively small subgroup of our infants who526
were breastfed. Regardless, this is a topic which warrants further investigation.527
Regardless of the extent to which factors other than antibiotic administration528
influence these results, there is a concern that these short-term changes to the529
microbiota may in turn have long-term health consequences in the form of530
allergies, asthma etc. later in life (13, 25). While follow up analysis of these531
infants was outside the scope of this short-term study, we hope to return to this532
topic in future studies.533
In conclusion, this study has shown the altered microbiota, over 8 weeks, of a534
group of infants who were in receipt of parenteral antibiotic treatment within the535
first 48 hours of life. To our knowledge, this is the first study to use high-536
throughput sequencing of 16S rRNA and/or rpoB amplicons to accurately assess537
these impacts. While the results may reflect a combination of several538
environmental effects in early life, it would appear that antibiotic administration is539
the most influential factor. It would thus seem that, where available, the use of540
narrow spectrum antibiotics coupled with the use of pre and probiotics should be541
considered with a view to minimizing the risk of long-term health effects. While it542
is evident that the study of the composition of the infant gut microbiota and the543
consequence of antibiotic treatment on this population requires further544
investigation, it is anticipated that the further application of high-throughput545
sequencing technologies (including those used in long-term follow up trials) will546
shed additional light as to the optimal strategies to employ to control infection,547
while minimising the risks to commensal microbes.548
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TABLE 1. Details of the infants in the trial
Infant Sex* Mode of delivery Feeding method Duration of
antibiotic
treatment
(days)
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
M
M
M
M
F
F
F
M
M
M
M
F
F
M
F
M
M
F
Caesarean section
Caesarean section
Caesarean section
Vaginal delivery
Caesarean section
Vaginal delivery
Vaginal delivery
Caesarean section
Vaginal delivery
Vaginal delivery
Vaginal delivery
Vaginal delivery
Vaginal delivery
Vaginal delivery
Vaginal delivery
Vaginal delivery
Vaginal delivery
Vaginal delivery
Breastfed
Breasfed+Formula
Breastfed
Formula
Formula
Breastfed
Breastfed
Formula
Formula
Formula
Formula
Formula
Formula
Breastfed
Breastfed
Breastfed
Formula
Formula
9
5
2
2
5
2
2
2
2
-
-
-
-
-
-
-
-
-
* M, male; F, female. Table adapted with permission from Ref 29.
- 40 -
TABLE 2. Estimation of diversity within the treated and control groups at week 4 and
week 8
Data set Treated
week 4
Control
week 4
Treated
week 8
Control
week 8
Similarity
Chao 1 richness estimation
Shannon’s index for diversity
Good’s coverage
97%
243
3.6
96.1
97%
364
3.8
94.3
97%
334
3.8
93.2
97%
490
4.6
88.6
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TABLE 3. Total bacteria numbers given as copies of 16S rRNA/g wet stool in treated
and controls samples at week 4 and week 8.
P values based on Mann Whitney analysis, with statistical significance determined as
p< 0.05. P values are indicating if statistically significant differences exist between total
bacterial numbers in each infant between week 4 and week 8.
Treated Wk 4 Wk 8 P Controls Wk 4 Wk 8 P
B
F
G
H
Average
9.79x107
5.89x107
3.28x107
3.52x107
4.78x107
6.57x107
3.53x108
7.79x107
6.43x108
2.48x108
0.7728
0.0809
0.0518
0.1489
0.0005
K
L
M
N
6.23x107
2.19x107
2.37x107
9.05x107
4.96x107
7.35x107
3.61x108
2.18x108
5.75x106
1.91x107
0.1489
0.0809
0.0518
0.0765
0.0289
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TABLE 4. Total bifidobacteria numbers as CFU/g infant stool in the treated and control
samples at week 4 and week 8
Treated Wk 4 Wk 8 P Controls Wk 4 Wk 8 P
B
F
G
H
Average
1.49x104
7.32x106
2.51x105
5.55x107
1.58x107
1.76x107
1.10x109
1.93x105
4.57x108
3.94x108
0.0814
0.0809
0.2472
0.0304
K
L
M
N
O
6.62x107
7.95x106
1.48x106
4.75x106
5.05x107
2.62x107
5.98x105
5.11x104
2.39x108
5.47x106
1.14x108
7.18x107
0.0809
0.0809
0.0809
0.7728
0.0369
P values based on Mann Whitney analysis, with statistical significance determined as
p< 0.05. P values are calculated with respect to differences in total bifidobacteria
numbers within individual infants between week 4 and week 8.
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Figure legends.
FIG. 1. Microbial distributions at phylum level in the treated and control samples at
week 4 and week 8. Statistically significant differences between treated samples and
controls at week 4 are denoted by * (where p< 0.05). Statistically significant differences
between treated samples and controls at week 8 are denoted by *. A statistically
significant difference between treated samples at week 4 and at week 8 (i.e. the
recovery of the treated samples) is denoted by ♦. Percentages are based on proportion 
of assignable tags.
FIG. 2. Microbial distributions at the family level in the treated and control samples at
week 4 and week 8. Statistically significant differences between treated samples and
controls at week 4 are denoted by * (where p<0.05). Statistically significant differences
between treated samples and controls at week 8 are denoted by *. A statistically
significant difference between treated samples at week 4 and at week 8 (i.e. the
recovery of the treated samples) is denoted by ♦. Percentages are based on proportion 
of assignable reads.
FIG. 3. Microbial distributions at the genus level in the treated and control samples at
week 4 and week 8. Statistically significant differences between treated samples and
controls at week 4 are denoted by * (where p<0.05). Statistically significant differences
between treated samples and controls at week 8 are denoted by *. A statistically
significant difference between treated samples at week 4 and at week 8 (i.e. the
recovery of the treated samples) is denoted by ♦. Percentages are based on proportion 
of assignable reads.
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FIG. 4. Individual distributions of bifidobacteria in the treated (B1-H1; B2-H2) and
control samples (J1-R1; J2-R2) as detected using rpoB amplicons for 454-
pyrosequencing. Values show the percentage of the different bifidobacteria species
present in the individual samples. Treated samples show far less variability both
between treated samples and also between week 4 and week 8 compared to the
controls. X-axis indicates the individual infants; y-axis percentage of total bifidobacteria
assigned to each species.
